lenalidomide has been researched along with Abnormal Karyotype in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Döhner, K; Gabdoulline, R; Ganser, A; Ganster, C; Germing, U; Göhring, G; Gutermuth, A; Haase, D; Haferlach, C; Haferlach, T; Heuser, M; Kandziora, C; Klement, P; Klesse, S; Kobbe, G; Koenecke, C; Kröger, N; Krönke, J; Kubasch, AS; Meggendorfer, M; Mies, A; Panagiota, V; Platzbecker, U; Schiller, J; Schlegelberger, B; Schroeder, T; Shahswar, R; Shirneshan, K; Sperr, WR; Thiede, C; Thol, F; Valent, P | 1 |
| Gironella, M; López-Andreoni, L; Mallo, M; Martínez-Morgado, N; Ortega, M; Sánchez-Morata, C; Solé, F; Valcárcel, D; Vallespí, T | 1 |
2 other study(ies) available for lenalidomide and Abnormal Karyotype
| Article | Year |
|---|---|
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Alleles; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Protein Phosphatase 2C; Retrospective Studies | 2021 |
5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Topics: Abnormal Karyotype; Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |